Lv12
20 积分 2025-09-18 加入
Convergent Proteinuria Reduction across Distinct Therapeutic Pathways in IgA Nephropathy
1天前
求助中
Convergent Proteinuria Reduction across Distinct Therapeutic Pathways in IgA Nephropathy
1天前
求助中
A case of adrenal insufficiency after initiation of targeted-release budesonide formulation (Nefecon) in a patient with IgA nephropathy
1天前
求助中
Endothelin Receptor Antagonist Ambrisentan, SGLT2 Inhibitor Henagliflozin, and Their Combination in IgA Nephropathy
1天前
已完结
Telitacicept Add Glucocorticoids Versus Telitacicept Alone in the Treatment of IgA Nephropathy: A Real‐World Study
6天前
已完结
A targeted-release formulation of budesonide for the treatment of IgA nephropathy patients with severe renal impairment
5个月前
已完结
Efficacy and Safety of Nefecon in Patients with Immunoglobulin A Nephropathy from Mainland China: 2-Year NefIgArd Trial Results
5个月前
已完结
Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)
6个月前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
7个月前
已完结
皖公网安备34019202002308
